Olymvax Biopharmaceuticals Inc. (SHA: 688319), a leading vaccine specialist headquartered in Chengdu, China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its tetravalent influenza virus split vaccine (MDCK cells). This vaccine is designed to prevent influenza caused by vaccine-related influenza viruses in individuals aged six months and above.
The vaccine, cultured using MDCK cells in a bioreactor, represents a cell-based approach to influenza vaccination. This method allows for large-scale production, offering higher yields, more consistent product quality, and reduced manufacturing costs. The vaccine is expected to stimulate immune responses against the influenza virus, thereby preventing illness from vaccine-related strains.- Flcube.com
